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Genomic Duplication and Overexpression of TJP2/ZO-2
Leads to Altered Expression of Apoptosis Genes
in Progressive Nonsyndromic Hearing Loss DFNA51
Tom Walsh,1,8 Sarah B. Pierce,1,8 Danielle R. Lenz,2 Zippora Brownstein,2 Orit Dagan-Rosenfeld,2
Hashem Shahin,3 Wendy Roeb,1 Shane McCarthy,4 Alex S. Nord,1 Carlos R. Gordon,5 Ziva Ben-Neriah,6
Jonathan Sebat,4,9 Moien Kanaan,3 Ming K. Lee,1 Moshe Frydman,2,7 Mary-Claire King,1,*
and Karen B. Avraham2,*
Age-related hearing loss is due to death over time, primarily by apoptosis, of hair cells in the inner ear. Studies of mutant genes respon-
sible for inherited progressive hearing loss have suggested possible mechanisms for hair cell death, but critical connections between
these mutations and the causes of progressive hearing loss have been elusive. In an Israeli kindred, dominant, adult-onset, progressive
nonsyndromic hearing loss DFNA51 is due to a tandem inverted genomic duplication of 270 kb that includes the entire wild-type gene
encoding the tight junction protein TJP2 (ZO-2). In the mammalian inner ear, TJP2 is expressed mainly in tight junctions, and also in
the cytoplasm and nuclei. TJP2 expression normally decreases with age from embryonic development to adulthood. In cells of affected
family members, TJP2 transcript and protein are overexpressed, leading to decreased phosphorylation of GSK-3b and to altered expres-
sion of genes that regulate apoptosis. These results suggest that TJP2- and GSK-3b-mediated increased susceptibility to apoptosis of cells
of the inner ear is the mechanism for adult-onset hearing loss in this kindred and may serve as one model for age-related hearing loss
in the general population.Age-related hearing loss is an extremely common problem
worldwide. It is caused by the loss over time, primarily
by apoptosis, of nonregenerative hair cells in the inner
ear.1,2 In a large kindred from Israel, a gene responsible
for progressive adult-onset hearing loss provides a clue to
the mechanisms linking apoptosis to age-related hear-
ing loss. Heretofore, genes responsible for hearing loss
have been identiﬁed through point mutations, insertions,
or deletions. Array comparative genomic hybridization
(arrayCGH) enables genome-wide discovery of more com-
plex mutations, such as microdeletions or microduplica-
tions, responsible for hearing loss. With arrayCGH, we
identiﬁed DFNA51 (MIM 612642) as an inverted genomic
duplication of the tight junction protein gene TJP2 (MIM
607709), leading to overexpression of the TJP2 protein
and altered expression of genes that regulate apoptosis.
Overexpression of TJP2 implicates the GSK-3b pathway
in apoptosis leading to progressive hearing loss.
Family T, of Jewish ancestry, immigrated to Israel from
Tunisia in 1951. In recent years, relatives in the kindred
have sought medical advice for progressive hearing loss
(Figure 1A). Pure tone audiometry revealed hearing loss
with onset in the fourth decade, progressing ﬁrst at high
frequencies and ultimately becoming severe to profound
at all frequencies (Figure 1B). There were no complaints of
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The Aindividuals, as evaluated by the ocular motor and vestib-
ular examination.3 Genome-wide linkage analysis, under a
model postulating a dominant highly penetrant suscepti-
bility allele, was undertaken for 58 relatives from family
Taged 30 years and older. Of the 350microsatellite markers
tested, only one marker yielded a lod score > 3.0: at
D9S175, Z ¼ 6.56 (theta ¼ 0). Genotypes of multiple addi-
tional microsatellite markers ﬂanking D9S175 revealed
perfect linkage of the phenotype to chromosome 9p13.3-
q21.13 from 38.177 MB to 79.921 MB (hg19) (Figure 1C).
This genomic region harbors more than 80 known genes,
including the transmembrane channel gene TMC1 (MIM
606706), mutations in which are responsible for DFNA36
(MIM 606705) and DFNB7/11 (MIM 600974).4 We
sequenced TMC1 from genomic DNA and from cDNA iso-
lated from lymphoblasts of affected individuals of family
T and found no rare variants coinherited with hearing
loss. In addition, heterozygosity at rs2589615 in TMC1
exon 6 indicated that both TMC1 messages were present
in lymphoblasts of affected individuals. By using genomic
DNA from relatives of family T, we sequenced exons and
ﬂanking regulatory regions of 20 other genes (including
TJP2) in the linked region. No deleterious mutations were
detected in these 21 genes.
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Figure 1. Linkage Analysis and Identification of the Inverted Genomic Duplication in Family T
(A) Family T with progressive hearing loss indicated by ﬁlled symbols.
(B) Audiogram of hearing loss by age.
(C) Chromosome 9 region of linkage to the hearing loss phenotype. Recombinant individuals are indicated in the notation of (A).
(D) arrayCGH scan indicating the family-speciﬁc duplication of ~270 kb in genomic DNA of II-7. arrayCGH also detected homozy-
gosity for a polymorphic deletion of 8760 bp within the larger novel duplicated region. The study was approved by the Helsinki
Committees of Tel Aviv University and the Israel Ministry of Health and by the Human Subjects Division of the University of
Washington.(segdups) and is prone to microdeletions and microdupli-
cations.5 In order to evaluate this region for microdeletions
and microduplications in family T, we screened genomic
DNA from affected individual II-7 by arrayCGH with the
Nimblegen HD2 platform with the previously described102 The American Journal of Human Genetics 87, 101–109, July 9, 20CHP-SKN sample6 as the reference. Data were normalized
and CNVs were called by identifying regions where
Z-scores consistently deviated from the diploid mean.
At 9q21.11, a genomic duplication of ~270 kb was
apparent in the genomic DNA of II-7 (Figure 1D). The10
Figure 2. Characterization of the Inverted Duplication at TJP2
(A) Sketch of the inverted duplication.
(B) PCR products, ~7 kb in size, ampliﬁed with primers speciﬁc to the inverted duplication, from genomic DNA of affected (A) and unaf-
fected (Un) relatives of family T.duplication spanned 218 probes, with a median Z-score of
2.2. This duplication was not observed in the Database of
Genomic Variants (March 25, 2010 update).
Genomic duplications may or may not be in tandem
with their parent segment and may be either in the same
or inverted orientation.7 We developed primers that would
uniquely amplify genomic DNA with the duplication
under each of these conditions. Forward (50-CCCAGCAGA
AGCAATGGTGGTAGCC-30) and reverse (50-GGTGGTGAA
TCCAAAAACACAAGAACAAAGTC-30) primers diagnostic
for a tandem inverted duplication (Figure 2A) yielded prod-
ucts of expected size in family T relatives with hearing loss,
but yielded no product in unaffected family T relatives
(Figure 2B). Genotypes of all 58 participating relatives in
family T indicated that the tandem inverted duplication
was coinherited with hearing loss. The duplication spans
approximately positions 71,705,804 to 71,974,823 (hg19)
on chromosome 9 for a size of ~269,023 bp. The duplica-
tion includes the entire locus for the tight junction protein
TJP2, which spans positions 71,788,971 to 71,870,124
(hg19).
The distal breakpoint of the inverted duplication occurs
in intron 2 of FAM189A2 (also named c9orf61). The anno-
tated human sequence of FAM189A2 indicates exon 1 to
be noncoding and exon 2 to include only four translated
codons. However, at the orthologous mouse sequence
Fam189a2,most of exon 1 is an open reading frame begin-
ning with Met, and together with exon 2 is predicted to
encode 150 amino acids. Genomic sequence of human
and mouse are very similar in this region. We carried out
RT-PCR from human fetal brain and human lymphoblast
RNA and found that the human and mouse transcripts are
conserved (data not shown). However, with 30 rapid ampli-
ﬁcation of cDNA ends (30 RACE), we found no evidence of
a mutant FAM189A2 transcript in carriers of the genomic
duplication, suggesting that no truncated FAM189A2
product was made. In addition, there was no correlation
of genotype with expression of full-length FAM189A2
transcripts among family T relatives (Figure S1 available
online). We thus focused on the duplication of TJP2 as the
likely cause of the hearing loss in family T.The AIn order to characterize expression of Tjp2 during devel-
opment, we assessed levels of Tjp2 transcript expression
in the mouse ear by quantitative RT-PCR of RNA from
wild-type C3H mice at ages E16.5, P0, 1 week, 1 month,
3 months, and 9 months (Figure 3A). Total RNA was har-
vested from mouse whole inner ears and reverse tran-
scribed with random primers. Quantitative PCR (qPCR)
was performed on an ABI 7900HT Real-Time PCR System,
according to manufacturer’s instructions and with the
TaqMan Gene Expression Assays indicated in Table S1.
Relative to levels of the internal control Hprt, Tjp2 expres-
sion decreased rapidly between E16.5 and 1 week to a level
in adult mice approximately 50% the level at birth.
We evaluated localization of Tjp2 protein in the mouse
inner ear at various ages by immunohistochemistry of
parafﬁn-embedded sections (Figure 3). In the cochlea,
Tjp2 is localized most prominently in membranes con-
necting hair cells and supporting cells (Figure 3C). Tjp2
is also localized in membranes connecting the cells of
the vestibular system (Figure 3D). Localization is punctate
and most concentrated at membrane boundaries, as ex-
pected for junctional staining.8 In the hair cell, Tjp2 is
localized both at the apical edge, associated with tight
junctions, and also along the basolateral side. In most
epithelial cells, the basolateral side contains adherens junc-
tions, but in the inner ear, apical and basal junctions are
not distinct but form a combined structure, the tight-adhe-
rens junction, between outer hair cells and supporting
Deiter cells.9 To a lesser extent, Tjp2 is also localized to
both the cytoplasm and nucleus, presumably reﬂecting
its role in signal transduction.10 The contrast between
localization of Tjp2 and the closely related Tjp1 is illus-
trated in Figure S2.
By both genomic position and function, TJP2 is an excel-
lent candidate for the gene responsible for hearing loss
in family T. However, the sequence of TJP2 in family T is
wild-type. In order to evaluate how genomic duplication
of wild-type TJP2 might lead to progressive hearing loss,
we compared expression of TJP2 in lymphoblasts of family
T relatives carrying the duplication versus relatives not
carrying the duplication. In cells of individuals with themerican Journal of Human Genetics 87, 101–109, July 9, 2010 103
Figure 3. Expression of Tjp2 in the Mouse Inner Ear
(A) Expression of Tjp2 transcript at ages E16.5, P0, 1 week, 1 month, 3 months, and 9 months, determined by real-time qPCR, reveals
decline with age until after hearingmaturation at P30, then a stable level during adulthood. Values represent mean5 SD of samples run
in triplicate. The experiment was repeated twice; a representative experiment is shown.
(B) Schematic representation of the P0 cochlea (top) and saccule (bottom). The inner and outer hair cells of the cochlea make up the
sensory epithelium; nonsensory supporting cells include Deiters’, pillar, and Hensen cells. The saccule contains sensory hair cells and
nonsensory supporting cells.
(C and D) Immunoﬂuorescence confocal images of the cochlea (C) at E16.5 and P0 and of the saccule (D) at E16.5. Tjp2 expression (red)
is seenmainly at cell junctions (arrowheads) and also in the cytoplasm and nuclei (arrows) of hair cells and adjacent supporting cells. The
vestibular pattern of expression was similar in the utricle and cristae at these ages (data not shown). Negative control staining of P0
cochlea without primary antibody against Tjp2 demonstrates the low background of the secondary antibody. Hair cell cytoplasm and
nuclei are marked bymyosin VI (MyoVI, green) and DAPI (blue), respectively. Parafﬁn-embedded sections were stained with the primary
antibodies goat anti-myosin VI (Santa Cruz Biotechnology), rabbit anti-ZO-2 (Cell Signaling), and mouse anti-ZO-1 (Zymed) and the
ﬂuorescence-conjugated secondary antibodies donkey anti-goat 488, donkey anti-rabbit 594, and donkey anti-mouse rhodamine
(Molecular Probes). Imaging was done with the LSM 510 confocal microscope (Zeiss). All procedures involving animals met NIH guide-
lines and were approved by the Animal Care and Use Committees of Tel Aviv University and the University of Washington. Scale bar
represents 10 mm.duplication, endogenous levels of TJP2message, relative to
18S rRNA, were elevated approximately 1.7-fold (Mann-
Whitney U test, p ¼ 0.002) (Figure 4A). Endogenous levels
of TJP2 protein were elevated approximately 2-fold (Fig-
ures 4B and 4C).104 The American Journal of Human Genetics 87, 101–109, July 9, 20Experimental overexpression of TJP2 has been shown to
decrease phosphorylation of the serine/threonine protein
kinase GSK-3b at position serine 9.11 Phosphorylation at
Ser9 is known to inhibit the kinase activity of GSK-3b.12,13
In order to determine the consequences of endogenous10
Figure 4. Overexpression of TJP2 and Reduced Phosphorylation of GSK-3b Associated with the Genomic Duplication
(A) Expression of TJP2 transcript in lymphoblasts of family T relatives with (DUP) and without (WT) the genomic duplication, deter-
mined by real-time qPCR. Values represent mean 5 SEM of data from three independent experiments, which included cells from
four individuals without the duplication and six with the duplication.
(B–E) Lymphoblast cell lysates of family T relatives were analyzed by immunoblotting with primary antibodies rabbit anti-TJP2 (Santa
Cruz Biotechnology), mouse anti-GSK-3b (BD Transduction Laboratories), rabbit anti-phospho(Ser9)-GSK-3b (p-GSK-3b) (Cell Signaling
Technology), and mouse anti-b-actin (Sigma) and IRDye-conjugated secondary antibodies (LI-COR Biosciences). Levels of TJP2 relative
to b-actin (B) and levels of p-GSK-3b relative to GSK-3b (D) were quantiﬁed from western blots (C, E). Blue bars represent results from
individuals without the duplication; red bars represent results for individuals with the duplication. Individuals are labeled as in Figure 1.
Values in (B) and (D) represent mean5 SEM of data from three independent experiments; representative western blots are shown.overexpression of TJP2, we evaluated phosphorylation of
GSK-3b at Ser9 in cells of individuals with and without
the genomic duplication (Figures 4D and 4E). The levels
of total GSK-3b were similar, but the amount of phos-
phorylated GSK-3b was lower in cells of persons with the
duplication. The decreased ratio of phosphorylated to un-
phosphorlylated GSK-3b suggests that GSK-3b activity was
higher in cells with the duplication.
Apoptosis of cells in the cochlea, including transcrip-
tional changes in genes involved in apoptosis, has been
implicated in age-related hearing loss in mice,14–16 as well
as in hearing loss induced by acoustic overstimulation17
and chemotherapeutic agents.18 Because GSK-3b has been
shown to promote the mitochondrial intrinsic apoptosis
pathway,13 and GSK-3b inhibitors can block cisplatin-
induced ototoxicity in mice,18 we investigated whether
genomic duplication of TJP2 led to changes in expression
of apoptosis-related genes. We screened lymphoblast cells
of four family T relatives, two with and two without the
duplication, for differential expression of 92 apoptosis-
related genes via human cellular apoptosis pathway plates
(Applied Biosystems). Expression of the apoptosis-related
genes was normalized to the expression of HPRT as an
endogenous control. Genes were chosen for further anal-
ysis if expression by genotype differed at least 2-fold withThe At test p < 0.2. Four genes (BCL2L11, IL6, REL, and TSPO)
were identiﬁed by these criteria (Table S2). On replication,
all four genes showed signiﬁcant differences in expression
with p< 0.01 (Figure 5A). Expression of BCL2L11, REL, and
TSPO was observed in mouse cochlea; IL6 was not detect-
ably expressed (data not shown).
BCL2L11 (also known as BIM) and TSPO can both
promote apoptosis via the intrinsic mitochondrial path-
way19–21 and REL can suppress apoptosis as a subunit of
the antiapoptotic transcription factor NF-kB.22 BCL2L11
(BIM) is a member of the BCL2 family of proteins, which
includes both pro- and antiapoptotic members. The
balance between pro- and antiapoptotic BCL2 family pro-
teins inﬂuences the sensitivity of cells to apoptosis.20,21
Only a subset of BCL2 family genes were evaluated in our
initial screen of 92 apoptosis-related genes. We were inter-
ested in whether any genes in this family in addition to
BCL2L11 (BIM) were differentially expressed in cells with
and without the genomic duplication. When the remain-
ing BCL2 family members20,21 were evaluated, we found
that three additional genes were differentially expressed
with p< 0.01. Expression of the proapoptotic gene BIDwas
elevated 1.7-fold and expression of the antiapoptotic iso-
form of BCL2L1 (BCL-xL) was decreased 1.4-fold. In addi-
tion, expression of the antiapoptotic BCL2L2 (BCL-w)merican Journal of Human Genetics 87, 101–109, July 9, 2010 105
Figure 5. Effects of the TJP2 Duplication on Expression of Apoptosis-Related Genes
Real-time qPCR analyses of RNA from lymphoblasts of family T relatives (blue and red bars and individual samples as in Figure 4).
(A) Expression of genes identiﬁed as differentially expressed in the screen of apoptosis-related genes.
(B) Expression of BCL2 family genes. Gene expression was normalized to the geometric mean of the expression of the endogenous
control genes HPRT, TBP, and UBC.41 Values represent mean 5 SEM of data from three independent experiments. The result for
BCL2L11 is indicated in both (A) and (B).was elevated 1.5-fold (Figure 5B). Based on the GEPIS and
UniGene databases, all of these genes are expressed in
mouse inner ear. Taken together, these data suggest that
in cells carrying the genomic duplication, there is an over-
all shift in expression of BCL2 family genes that would
favor apoptosis.
Tight junction proteins play multiple roles in epithelial
cells.23 Claudins, tricellulins, and zona occludins (TJP)
family members are critical to the formation of diffusion
barriers that regulate cellular permeability.24 In the inner
ear, tight junctions linking the cells of the sensory epithelia
are crucial for the maintenance of separation between
endolymphatic and perilymphatic ﬂuids, which differ in
their ionic composition.25 This separation and the con-
trolled transfer of ions, namely Kþ, under speciﬁc sound
and vibration conditions, allow the formation of the endo-
cochlear potential and the conversion of ﬂuid changes into
mechanical stimuli. Tight junctions ensure the strict
compartmentalization of these regions. Mutations in tight
junction proteins claudin-11, claudin-14, and tricellulin
lead to hearing loss.26–29
Tight junctions also participate in signal transduction
mechanisms that regulate cell proliferation and gene ex-
pression. TJP2 and related proteins are localized both at
tight junctions and in the nucleus. In the nucleus, TJP2
most probably functions in the regulation of gene expres-
sion by regulating nuclear import and export of transcrip-
tion factors and other proteins.30 TJP2 has been shown to
regulate GSK-3b,11 a serine/threonine kinase involved in
signal transduction pathways that regulate a wide range of
cellular processes. In response to various upstream signals,
GSK-3b is phosphorylated at Ser9, inhibiting its kinase
activity.12,13 Overexpression of TJP2 leads to a decrease in
GSK-3b Ser9 phosphorylation,11 thereby increasing GSK-
3b activity. Results for family T are consistent with this
pattern, in that levels of TJP2 transcript and protein are
elevated and GSK-3b-Ser9 phosphorylation is decreased in
lymphoblast cells of family T members carrying the TJP2106 The American Journal of Human Genetics 87, 101–109, July 9, 20duplication. Decreased GSK-3b-Ser9 phosphorylation is
an indicator of increased GSK-3b activity in these cells.
In various cell types, including neurons, increased GSK-
3b activity makes cells more susceptible to apoptosis.13
GSK-3b directly or indirectly regulates several key compo-
nents of the intrinsic apoptotic pathway, including
members of the BCL2 family. GSK-3b is required for the
induction of BCL2L11 (BIM) protein during stress- and
dexamethasone-induced apoptosis.31,32 Phosphorylation
by GSK-3b activates the proapoptotic BAX,33 which was
previously linked to age-related hearing loss,34 and destabi-
lizes the antiapoptotic MCL1.35 GSK-3b activity also regu-
lates permeability of the mitochondrial outer membrane
through phosphorylation of VDAC.36 In addition, phos-
phorylation of tau or kinesin by GSK-3b can disrupt micro-
tubules or intracellular protein transport, respectively,
which can also contribute to apoptosis.13 The gene expres-
sion changes in lymphoblast cells of TJP2 duplication
carriers indicate a shift toward increased expression of proa-
poptotic and decreased expression of antiapoptotic genes,
consistent with the known role of GSK-3b in promoting
apoptosis. Although the antiapoptotic BCL2L2 (BCL-w)
gene is slightly elevated, expression changes seen for other
BCL2 family members, as well as for TSPO and REL, prob-
ably shift the overall balance toward an increased sensi-
tivity to apoptosis. In addition to these transcriptional
changes, it is likely that elevatedGSK-3b activity also results
in posttranslational cellular changes favoring apoptosis.
We hypothesize that in the inner ear, as in lymphoblasts,
TJP2 overexpression results in changes in GSK-3b phos-
phorylation and apoptosis-related gene expression and
that these changes increase the susceptibility of inner ear
cells to apoptosis. Consistent with the hypothesis that
GSK-3b can regulate hair cell survival, inhibition of PI3
kinase signaling, which can negatively regulate GSK-3b,
blocked the ability of dexamethasone to protect cells
from ototoxicity in a rat model of trauma-induced hearing
loss.37 TJP2 is widely expressed, yet TJP2 overexpression10
via genomic duplication leads only to hearing loss. We
speculate that because the inner ear is a very sensitive
organ, a subtle difference in expression of genes in
apoptotic pathways is manifested in a hearing loss pheno-
type. Even a subtle increase in apoptotic susceptibility of
inner ear hair cells could account for the progressive
hearing loss of carriers of the TJP2 duplication. Our exper-
iments suggest that overexpressed TJP2 in family T modu-
lates intracellular signaling. This does not preclude the
possibility that excess TJP2 may also perturb the stability
of intercellular junctions and that this could also
contribute to the hearing loss in family T.
Hearing loss associated with overexpression of TJP2may
resemble age-related hearing loss generally in that both
involve apoptosis. The dramatic decrease in Tjp2 expres-
sion in the mouse ear by early adulthood suggests that
maintaining relatively low levels of Tjp2 from this stage
on may be important for maintaining normal inner ear
function throughout adulthood. In principle, other gain-
of-expression mutations in TJP2 could have a similar
effect. An amino acid substitution in TJP2 that segregates
with dominant progressive hearing loss has been reported
in a Guatemalan family, although levels of TJP2 transcript
and protein were not analyzed.38
A missense mutation in TJP2 has also been reported in
Amish families with oligogenic inheritance of hyperchola-
nemia (MIM 607748) involving mutations in both TJP2
and BAAT (MIM 602938). The TJP2 mutation, V48A, is in
the N-terminal PDZ domain and affects protein folding,
changing relative binding afﬁnities of TJP2 for different
claudins and leading to changes in ratios of claudins in
tight junctions.39 The relatives of family T do not have
any signs of familial hypercholanemia. In family T, TJP2
is overexpressed via genomic duplication, leading to
modulation of intracellular signaling, and, we suggest,
increasing the susceptibility of inner ear cells to apoptosis,
leading to progressive hearing loss.
The general consensus is that age-related progressive
hearing loss is due to loss ofhair cells over timebyapoptosis.
Although this is a common theme, the routes to apoptosis
are varied. Studies of mutant proteins responsible for
progressive hearing loss have suggested possible mecha-
nisms for hair cell death, including mechanical stress and
aberrations of DNA repair, cell cycle progression, and cell
signaling.40 In most of these cases, the critical connection
between the mutation and the cause of the progressive
hearing impairment remains elusive. The biology under-
lying progressive hearing loss in family T may offer one
such connection. Overexpression of TJP2 in carriers of the
genomic duplication suggests a mechanism for events
leading to apoptosis, and thus eventually to death of hair
cells and hearing loss in an extended family.Supplemental Data
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